CCR2 Antagonists for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases such as asthma, COPD, and atherosclerosis lack effective antagonists for CCR2, which are critical in regulating monocyte trafficking and inflammation.
Innovation Solution
Development of compounds according to general formula (I), which act as CCR2 inhibitors, specifically designed to block monocyte CCR2, thereby reducing macrophage-induced inflammation by binding to the receptor and modulating inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are used, then existing therapeutic options are available, but effective CCR2 antagonists are lacking to properly regulate monocyte trafficking and inflammation
Solution Approach 1:
The patent segments the inflammatory disease treatment approach by specifically targeting the CCR2 receptor pathway. The compounds disclosed are designed to selectively bind to and antagonize CCR2, separating this specific therapeutic action from general anti-inflammatory treatments. This allows for targeted intervention in monocyte trafficking without affecting other inflammatory pathways, thereby improving treatment reliability for CCR2-mediated conditions.
Solution Approach 2:
The CCR2 antagonist compounds act as intermediary substances that block the interaction between CCR2 receptors and their ligands (chemokines like MCP-1). By introducing these antagonist compounds as mediators, the patent prevents the harmful signaling cascade that leads to excessive monocyte recruitment and inflammation, while maintaining the natural receptor-ligand system intact for other physiological functions.
2Object-generated harmful factors
If monocyte CCR2 is blocked to reduce macrophage-induced inflammation, then inflammatory responses are reduced, but the mechanism requires effective antagonist compounds that do not yet exist
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of CCR2 antagonist compounds. The disclosed general formula (I) and its variants represent systematic variations in molecular parameters (substituents R1-R8, linker L1) to optimize binding affinity and selectivity for CCR2. This approach enables the development of effective antagonist compounds with improved pharmacological properties while maintaining the core mechanism of blocking CCR2 to reduce inflammation.
Data Source
AI summary
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.